Search Results
ASH 2013: Benefit of lenalidomide and low-dose dexamethasone
Benefit of treating smouldering myeloma patients early with lenalidomide & dexamethasone
FIRST trial: Continuous lenalidomide plus dexamethasone for newly diagnosed multiple myeloma
Pomalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma
ASH 2014: Phase III study of lenalidomide plus dexamethasone in smouldering myeloma
IMW 2011: Lenalidomide and dexamethasone to delay progression of smouldering multiple myeloma
Pomalidomide + Low-Dose Dexamethasone in Refractory or Relapsed & Refractory MM and Renal Impairment
ASH 2014: Highlights in multiple myeloma
EHA 2013: Pomalidomide prolongs survival in refractory multiple myeloma: Dr Jesus San Miguel
Graham Jackson, MD: Lenalidomide Maintenance Is Effective in All Types of Myeloma Patients
Current and Future Treatment of Multiple Myeloma
Lenalidomide/Dexamethasone vs. Clarithromycin/Leanlidomide/Dexamethasone in Myeloma
